Get a Sample
Schedule a Meeting
Get a Sample
Table Of Content
July 2025
The global cardiac troponin market size is calculated at USD 4.3 billion in 2025 and is forecasted to reach around USD 10.51 billion by 2034, accelerating at a CAGR of 10.45% from 2025 to 2034. The North America market size surpassed USD 1.48 billion in 2024 and is expanding at a CAGR of 10.43% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global cardiac troponin market size accounted for USD 3.89 billion in 2024 and is predicted to increase from USD 4.3 billion in 2025 to approximately USD 10.51 billion by 2034, expanding at a CAGR of 10.45% from 2025 to 2034. The cardiac troponin market is growing quickly due to the increasing global prevalence of cardiovascular diseases. The rising demand for point-of-care testing and high-sensitivity assays further support market growth.
Artificial intelligence is disrupting the cardiac troponin market by enhancing speed, accuracy, and availability of the test. AI optimizes troponin test results accurately, reducing errors and enhancing decision-making. A rapid troponin test, combined with machine learning algorithms, can identify the risks of a heart attack more quickly and accurately.
The U.S. cardiac troponin market size was exhibited at USD 1.03 billion in 2024 and is projected to be worth around USD 2.82 billion by 2034, growing at a CAGR of 10.60% from 2025 to 2034.
What Made North America the Dominant Region in the Cardiac Troponin Market?
North America dominated the market by capturing the largest share in 2024. This is mainly due to heightened awareness of cardiovascular health and increased adoption of sophisticated diagnostic tools in emergency care systems. There is a high utilization of high-sensitivity troponin assays, which are not widely adopted in other regions. The region has environments conducive to rapid and reliable evaluation of a burgeoning elderly population with escalating heart disease. There is also a plethora of stakeholders in the medical diagnostics sphere, including pharmaceutical and device companies that have ongoing clinical studies, which help drive innovation, increase the number of companies investing in the cardiac troponin market, and continue to make North America the global leader in cardiac troponin testing.
The U.S. is at the apex of North America's cardiac troponin market. This is mainly due to the high incidence of acute coronary syndrome and heart failure, and the timeliness of troponin testing is critical when diagnosing these medical conditions. As per the CDC, heart disease continues to be the leading cause of death in the U.S.
What Makes Asia Pacific the Fastest-Growing Region in the Cardiac Troponin Market?
Asia Pacific is the fastest-growing region in the cardiac troponin market because of its increasing burden of cardiovascular disease, improved access to healthcare, and growing awareness of early cardiac diagnostics. Both governments and private providers are beginning to invest in healthcare infrastructure, while the latter are also leveraging advanced diagnostics for clinical use. Additionally, the threat of further disease and the increasing affordability of new point-of-care testing and innovation are leading to the erosion of outdated market behaviors in specialty diagnostic markets on a macro level, in both rural clinics and urban hospitals.
India is emerging as a prominent player in the Asia Pacific cardiac troponin market, driven by its large population size and increasing prevalence of heart disease. Based on figures released by the Indian Council of Medical Research (ICMR), cardiovascular disease is now the leading cause of death in both rural and urban areas. The Indian government aims to strengthen primary and emergency care and is also seeking to expand access to cardiac diagnostics through public-private partnerships. The rising demand for decentralized diagnostics further supports market growth.
The cardiac troponin market refers to the global landscape of diagnostic solutions used for detecting cardiac troponin proteins (cTnI and cTnT) in blood, which are highly specific and sensitive biomarkers for myocardial infarction (MI) and acute coronary syndromes (ACS). Troponins are structural proteins released into the bloodstream when heart muscles are damaged, and their rapid and accurate detection is vital for early diagnosis and timely treatment. The market includes instruments, reagents, and assays used in point-of-care and laboratory settings across hospitals, clinics, and diagnostic laboratories.
| Report Coverage | Details |
| Market Size by 2034 | USD 10.51 Billion |
| Market Size in 2025 | USD 4.3 Billion |
| Market Size in 2024 | USD 3.89 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 10.45% |
| Dominating Region | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Type, Test Type, Sample Type, Technology, End Use, Application and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Rising Demand for Rapid Diagnostics
One of the major factors driving the growth of the cardiac troponin market is the rising demand for rapid, high-sensitivity troponin (hs-cTn) testing. Recent reports have demonstrated that U.S. entities have shown hs-cTn assays to have not only improved analytical specificity for myocardial injury indications, but also to improve patient outcomes and processing efficiencies in the emergency care continuum. Laboratory guidelines recommend hs-cTn test results be communicated to physicians in less than sixty minutes from the receipt of the sample, and some point-of-care devices can deliver results in less than twenty minutes.
(Source: https://www.sciencedirect.com)
The clinical practice framework of health systems across North America has now incorporated rapid troponin-based clinical pathways that safely rule out myocardial infarction in 1-2 hours, relieving some congestion in emergency rooms and increasing patient flow. Diagnostic protocols sanctioned by the government, as well as Laboratory Standards, have only solidified the utility and impact of fast and reliable troponin assays, creating a large demand for the global supply chain and infrastructure supporting and testing.
Regulatory Hurdles
A significant factor limiting the growth of the cardiac troponin market is the strict regulatory requirements imposed by Europe’s In Vitro Diagnostic Medical Device Regulation (IVDR), which has heightened approval barriers and hindered the availability of new or laboratory-developed troponin assays. The IVDR imposes stringent performance validation, clinical evidence, and post-market surveillance requirements, necessitating confirmation of follow-up activities in relation to the requirements under the previous IVDD scheme.
Many former in-house tests, including laboratory-developed tests, must now either be fully compliant or must be reclassified, while the notifying bodies under the member state’s capacity are constrained. These regulatory cultures limit the speed-to-market of new high-sensitivity and point-of-care troponin assays, especially in Europe and nearby markets, and curtail overall accessibility for clinicians as demand rapidly increases.
Opportunity
Will Point-of-Care Troponin Testing Change the Future of the Market?
One of the greatest opportunities in the cardiac troponin market is the rapid adoption of point-of-care (POC) technologies, particularly in emergency settings or for remote care. In November 2024, the U.S. FDA approved Abbott's i-STAT TnI-Nx assay for use in ER settings, providing troponin I results, allowing much faster diagnosis of myocardial infarction. POC testing is beneficial for hospitals that lack adequate testing solutions. POCT allows rapid troponin testing at the patient’s bedside, reducing turnaround times and improving patient management. (Source: https://clinicaltrials.gov)
Furthermore, the World Health Organization (WHO) has prioritized the expansion of decentralized diagnostic testing tools as part of its Global Health Emergency preparedness plan. Cardiovascular diseases are still the leading cause of mortality globally, which makes fast and portable troponin diagnostics a strong opportunity to hasten clinical decisions and increase access to care for patients in need.
Why Did the Troponin I (cTnI) Segment Dominate the Cardiac Troponin Market in 2024?
The troponin I (cTnI) segment dominated the market with the largest share in 2024. The dominance of the segment stems from its ability to provide the highest cardiac specificity and sensitivity for diagnosing myocardial infarction. Additionally, troponin is widely accepted by clinicians and regulatory agencies as a valuable biomarker for cardiac muscle injury, particularly in acute care and emergency settings. cTnI document reliability and clinical verification for laboratory-based platforms.
The troponin T (cTnT) segment is expected to grow at the fastest rate in the coming years, primarily due to its increased use in high-sensitivity assays and its widespread application in risk stratification, as well as in the management of chronic cardiac conditions. Its greatest potential lies in identifying more subtle cardiac events, such as other troponin types, as well as in following invasive procedures and/or monitoring the progression of heart failure. Given the increased demand for accurately tracking the cardiac state of patients, either longitudinally or as part of an acute case, cTnT product types will continue to grow in both institutional and outpatient settings. cTnT's eventual usage limitations and refinements will drive the application of troponin to new detection innovations, particularly when integrated into more advanced technology platforms and/or as point-of-care devices.
What Made Laboratory-Based Testing the Dominant Segment in the Cardiac Troponin Market in 2024?
The laboratory-based testing segment led the market with the largest share in 2024, as it is generally considered more accurate and sensitive. This test finds widespread applications in hospitals and clinics. Laboratory tests are especially important in diagnosing acute myocardial infarction and are typically performed in emergency departments, regardless of whether the troponin test is sent to an outside laboratory. The rising demand for more advanced testing technologies, such as chemiluminescence immunoassays (CLIA), further supports segmental growth.
The point-of-care testing (POCT) segment is expected to grow at the fastest CAGR in the upcoming period, as healthcare systems increasingly favor more rapid diagnostics in emergency rooms, ambulances, and rural areas. POCT allows for the identification of any elevated cardiac troponin, thereby reducing the risk of heart attacks. POCT helps enhance decision-making, improving patient outcomes. Additionally, the increasing development of sophisticated POCT devices contributes to segmental growth.
How Does the Serum Segment Lead the Market in 2024?
The serum segment led the market in 2024, as it is the predominant sample type for cardiac troponin testing due to both organizational and clinical laboratory acceptance, as well as its compatibility with standard diagnostic procedures. In addition, serum provides a clean matrix that enables accurate and sensitive detection of troponin levels based on techniques such as chemiluminescence immunoassays (CLIA). Serum samples are routinely used in many hospitals and emergency department settings, as they provide reproducible results for diagnosing myocardial infarction. The clear infrastructure associated with serum processing at clinical laboratories has led to its continued adoption in routine, acute, and emergency cardiac care settings.
The others (e.g. fingerstick samples) segment is likely to grow at a significant CAGR during the projection period. This is mainly due to the increasing development of point-of-care testing and decentralized diagnostic tests that utilize non-serum samples. These samples facilitate rapid, minimally invasive testing, which could be particularly advantageous in emergency transport (e.g., in an ambulance), in rural clinics, and in home care environments. In addition to their obvious ease of use, the push for rapid clinical decision-making and better reach into lower-resource environments has led to the widespread adoption of non-serum-based cardiac troponin testing.
Why Did the Chemiluminescence Immunoassay (CLIA) Segment Dominate the Cardiac Troponin Market in 2024?
The chemiluminescence immunoassay (CLIA) segment held the largest share of the market in 2024. CLIA is the most widely used platform in cardiac troponin assessment because it is extremely sensitive, specific, and capable of generating fast and reliable results. CLIA is used extensively in hospital laboratories, enabling high-throughput testing in emergency or routine cardiac assessments. The strong performance of CLIA in the detection of low troponin concentrations is especially critical for the early diagnosis of myocardial infarctions. Moreover, compatibility with automated processing and sophisticated analyzers further enhances the clinical utility of CLIA and strengthens its position as the gold standard among troponin testing technologies.
The others segment is expected to grow at a significant CAGR during the forecast period. This is mainly due to the increasing demand for biosensors and electrochemical assays in cardiac troponin diagnostics. Emerging technologies enable point-of-care or wearable applications, allowing for the real-time monitoring of cardiac biomarkers in outpatient or non-traditional laboratory settings. With a growing emphasis on personalized and preventive healthcare, there is an increasing interest in these advanced platforms, given their ability to provide instantaneous results with minimal sample requirements.
How Does the Hospitals & Clinics Segment Dominate the Cardiac Troponin Market?
The hospitals & clinics segment dominated the cardiac troponin market in 2024, offering the benefits of centralized facilities to diagnose and manage acute cardiovascular conditions (such as myocardial infarction). These settings are outfitted with advanced laboratory infrastructure and staff, which are necessary to handle high-sensitivity assays. Because the rapid diagnosis of heart-related conditions is of paramount clinical importance, hospitals and clinics will continue to be the primary end-users of troponin diagnostics.
The homecare settings segment is expected to experience the fastest growth, given the global trend of remote monitoring and decentralized diagnostics. With an aging population contributing to the demand for post-discharge care, there is an increasing need for portable, easy-to-use cardiac testing devices that can be brought into patients' homes instead of being performed in a hospital or clinical setting. Technological advancements are significantly improving the quality of point-of-care and wearable troponin monitoring products, enabling patients and healthcare staff to easily monitor their heart health at home. This change supports the early detection of problems, reduces ER visits, and improves longer-term outcomes, making home-based testing an emerging area within cardiac care.
Why Did the Myocardial Infarction Diagnosis Segment Dominate the Cardiac Troponin Market in 2024?
The myocardial infarction diagnosis segment has remained the leading application segment in the cardiac troponin testing because troponin is the gold standard biomarker for heart muscle injury. Troponin elevation during a heart attack is significant, and obtaining troponin measurements is critical for confirming or ruling out MI in emergency departments or acute-care settings. Hospitals, emergency departments, and other urgent care facilities routinely perform troponin assays on patients to inform important treatment decisions. The reliability, rapid turnaround time, and clinical diagnostic evidence provided by troponin in the identification of MI ensure the consistent application of troponin remains.
The acute coronary syndrome (ACS) risk stratification segment is expected to expand at the fastest rate because of a shift in focus to early intervention and individualized care in modern medicine. High-sensitivity troponin assays allow clinicians to evaluate patients at variable degrees of cardiovascular risk, even those that may not yet fully qualify a patient as having undergone a myocardial infarction. As preventive cardiology comes to the forefront, concurrent with evolving guidelines that consider troponin-based risk models, this application is likely to increase and be incorporated into outpatient paradigms and preventive cardiology initiatives.
By Type
By Test Type
By Sample Type
By Technology
By End Use
By Application
By Region
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
July 2025
July 2025
October 2023
August 2024